AXIO0053
SMAC.4M™ TagRFP Smooth Muscle Cells (derived from mouse embryonic stem cells) 2M Kit with Puromycin and Medium
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352200
Pricing and availability is not currently available.
biological source
mouse embryo (stem cells)
form
liquid
color
fluorescent red, RFP
shipped in
liquid nitrogen
General description
SMAC.4M TAGRFP Smooth Muscle Cells are produced through in vitro differentiation of mouse embryonic stem (ES) cells and puromycin selection.
This kit includes:
- 1 vial of SMAC.4M TAGRFP Smooth Muscle cells 2M
- 1 vial of Puromycin 50uL
- 1 bottle of SMAC.4M Culture Medium-250ML
Application
Change media (SMAC.4M Culture Medium) at 24, and 48 hours after thaw. After 48 hours, change SMAC.4M Culture Medium with puromycin every 2-3 days. Supplement medium with puromycin (1 μg/mL) if the cells are cultured for > 1 week.
Rapidly thaw vial by gentle agitation in 37°C water bath (~2 minutes). Immediatly transfer the cell suspension into a 50 ml centrifuge tube filled with 8 ml SMAC.4M Culture Medium. Rinse the tube with an additional 1 ml of medium to collect remaining cells and pipette into the tube (10 ml total volume). Spin the cells at 200 x g (~1000 rpm) for 5 min. Resuspend the SMAC.4M TAGRFP Smooth Muscle Cells carefully in culture medium, seed on collagen-coated cultureware (approx. 1 x 105/cm2) and incubate at 37°C in a 5% CO2 atmosphere.
SMAC.4M TAGRFP Smooth Muscle Cells are genetically modified mouse cells and should be handled according to local directives (Biosafety level 1).
Stimulation by angiotension II, bradykinin, endothelin 1, or carbachol results in intracellular calcium mobilization and induces slow contractions of the cells.
The recommended culture media is SMAC.4M Culture Medium with Collagen I, Cat. No. C3867, extracellular matrix
Features and Benefits
SMAC.4M TAGRFP Smooth Muscle Cells are derived from transgenic mouse embryonic stem cells. These cells carry a puromycin resistance gene for chemical selection and a red fluorescent protein (TAGRFP) reporter gene. Both genes are under the control of a smooth muscle cell-specific promoter (Acta2 promoter).
SMAC.4M TAGRFP Smooth Muscle Cells have been evaluated to contract after stimulation by known inducers (e.g. angiotensin II, bradikynin, carbachol, endothelin I). Calcium transients can be measured using calcium dyes, even in HTS format (e.g. 384 well plates).
Quality
SMAC.4M TAGRFP Smooth Muscle Cells are 100% pure smooth muscle cells derived from transgenic mouse embryonic stem cells.
After thawing and plating, cells can be stimulated by various agents (e.g. angiotension II, bradykinin, endothelin-I, or carbachol), resuling in intracellular calcium mobilization and typical slow contractions of SMAC.4M TAGRFP Smooth Muscle Cells.
After thawing and plating, cells can be stimulated by various agents (e.g. angiotension II, bradykinin, endothelin-I, or carbachol), resuling in intracellular calcium mobilization and typical slow contractions of SMAC.4M TAGRFP Smooth Muscle Cells.
Preparation Note
For detailed protocols or application notes please email technical support [email protected]
Other Notes
This product includes cells shipped in liquid nitrogen dry vapor shippers.
Liquid nitrogen dry vapor shipper fee (up to a maximum of $125) and freight not included in price of product.
Liquid nitrogen dry vapor shipper is not disposable and should be returned after receipt. A $450 liquid nitrogen dry vapor shipper fee will be charged if not returned within 1 week of delivery.
Learn more about liquid nitrogen dry vapor shipper
Liquid nitrogen dry vapor shipper fee (up to a maximum of $125) and freight not included in price of product.
Liquid nitrogen dry vapor shipper is not disposable and should be returned after receipt. A $450 liquid nitrogen dry vapor shipper fee will be charged if not returned within 1 week of delivery.
Learn more about liquid nitrogen dry vapor shipper
Legal Information
AXIOGENESIS Label license
A Intellectual property rights
The Product is covered by patent families including but not limited to: EP1348019, EP1002080, EP1745144, EP1644485 and other patents pending. Purchase of the product does not transfer any rights other than those outlined below.
The purchase of this product conveys to the buyer the non-exclusive, non-transferable right to use the purchased amount of Cor.At cells and the associated Axiogenesis IP for (i) not-for-profit internal research conducted by the buyer and (ii) certain for-profit activities, including lead discovery, testing and/or research and development of products. The for-profit use in disease models and tissue models is expressly excluded.
B Use restrictions
This product is not suitable for any clinical, cell therapy, transplantation, regenerative medicine and clinical diagnosis applications. The purchaser shall not use the product in any way that contravenes applicable laws or regulations. The products should be used according to the User Guide. Failure to comply with any provisions in A B or C will make any warranty claims invalid. No rights are conveyed to modify, reproduce or clone any part contained in this product or to use Axiogenesis IP in any way that is separated from the purchased product.
C Other Patents
Axiogenesis products which were derived from iPS cells are covered by patents of patent family EP1970446 and US8048999 licensed from iPS Academia (Kyoto University)
Additionally GFP and RFP positive Products are covered by Patents owned by Evrogen. The GFP and RFP positive products are for internal non-commercial research use only. The right to use this GFP positive product specifically excludes the right to validate or screen compounds. For information on commercial licensing, contact Evrogen Licensing Department, email: [email protected].
Cor.At, Cor.4U and Mel.cor are trademarks of Axiogenesis AG, Cologne, Germany
Mitoexpress HS is a trademark of Luxcel, Cork, Ireland
TurboGFP and RFP are trademarks of Evrogen, Moscow, Russia
xCELLigence is a trademark of Roche Diagnostics GmbH, Mannheim, Germany
For information on the patents, patent applications and licenses contact Business Development Department, Axiogenesis AG, Email: [email protected]
A Intellectual property rights
The Product is covered by patent families including but not limited to: EP1348019, EP1002080, EP1745144, EP1644485 and other patents pending. Purchase of the product does not transfer any rights other than those outlined below.
The purchase of this product conveys to the buyer the non-exclusive, non-transferable right to use the purchased amount of Cor.At cells and the associated Axiogenesis IP for (i) not-for-profit internal research conducted by the buyer and (ii) certain for-profit activities, including lead discovery, testing and/or research and development of products. The for-profit use in disease models and tissue models is expressly excluded.
B Use restrictions
This product is not suitable for any clinical, cell therapy, transplantation, regenerative medicine and clinical diagnosis applications. The purchaser shall not use the product in any way that contravenes applicable laws or regulations. The products should be used according to the User Guide. Failure to comply with any provisions in A B or C will make any warranty claims invalid. No rights are conveyed to modify, reproduce or clone any part contained in this product or to use Axiogenesis IP in any way that is separated from the purchased product.
C Other Patents
Axiogenesis products which were derived from iPS cells are covered by patents of patent family EP1970446 and US8048999 licensed from iPS Academia (Kyoto University)
Additionally GFP and RFP positive Products are covered by Patents owned by Evrogen. The GFP and RFP positive products are for internal non-commercial research use only. The right to use this GFP positive product specifically excludes the right to validate or screen compounds. For information on commercial licensing, contact Evrogen Licensing Department, email: [email protected].
Cor.At, Cor.4U and Mel.cor are trademarks of Axiogenesis AG, Cologne, Germany
Mitoexpress HS is a trademark of Luxcel, Cork, Ireland
TurboGFP and RFP are trademarks of Evrogen, Moscow, Russia
xCELLigence is a trademark of Roche Diagnostics GmbH, Mannheim, Germany
For information on the patents, patent applications and licenses contact Business Development Department, Axiogenesis AG, Email: [email protected]
Cor.At is a trademark of Axiogenesis AG
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Chengming Gao et al.
Journal of experimental & clinical cancer research : CR, 41(1), 338-338 (2022-12-09)
Aberrant RNA editing of adenosine-to-inosine (A-to-I) has been linked to multiple human cancers, but its role in intrahepatic cholangiocarcinoma (iCCA) remains unknown. We conducted an exome-wide investigation to search for dysregulated RNA editing that drive iCCA pathogenesis. An integrative whole-exome
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
